La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Valerio Therapeutics Société anonyme Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Shefali Agarwal

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	3.1yrs
Proprietà del CEO	n/a
Durata media del management	1.4yrs
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

How Much Did Onxeo's (EPA:ALONX) CEO Pocket Last Year?

Dec 21

Recent updates

AMMINISTRATORE DELEGATO

Shefali Agarwal (51 yo)

3.1yrs

Mandato

Dr. Shefali Agarwal, M.D., M.P.H is President, CEO & Chairwoman of Valerio Therapeutics Société anonyme from April 07, 2022. Dr. Agarwal was Independent Director & President of Valerio Therapeutics Société...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Shefali Agarwal	President	3.1yrs	Nessun dato	Nessun dato
Joyce Carey	Executive Director of Finance and Head of FP&A	1.4yrs	Nessun dato	Nessun dato
Robin Sutherland	VP & Global Head of Human Resources	1.6yrs	Nessun dato	Nessun dato
Michel Forest	Chief Pharmacist & Quality Assurance Director	no data	Nessun dato	Nessun dato
Huiping Jiang	Senior Vice President of Regulatory Affairs & Quality Assurance	1.9yrs	Nessun dato	Nessun dato
Wael Jdey	Head of Preclinical	1.4yrs	Nessun dato	Nessun dato
Donna Cabral-Lilly	VP & Head of CMC	1.4yrs	Nessun dato	Nessun dato
Pam Slatcher	Head of Global PV	1.3yrs	Nessun dato	Nessun dato

1.4yrs

Durata media

Gestione esperta: Il team dirigenziale di ALVIO non è considerato esperto (durata media 1.4 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Shefali Agarwal	President	3.2yrs	Nessun dato	Nessun dato
Jacques Mallet	Independent Director	2.8yrs	Nessun dato	Nessun dato
Khalil Barrage	Representative Director	2.2yrs	Nessun dato	Nessun dato
Julien Miara	Director	3.9yrs	Nessun dato	Nessun dato
Nicolas Trebouta	Representative Director	13.2yrs	Nessun dato	Nessun dato
Ruth Plummer	Member of Scientific Advisory Committee	3.3yrs	Nessun dato	Nessun dato
Bryan Giraudo	Independent Director	2.8yrs	Nessun dato	Nessun dato
Robert Coleman	Independent Director	2.8yrs	Nessun dato	Nessun dato
Gilbert Chu	Member of Scientific Advisory Committee	3.3yrs	Nessun dato	Nessun dato
Gilles Favre	Member of Scientific Advisory Committee	3.3yrs	Nessun dato	Nessun dato
Lorenzo Galluzzi	Member of Scientific Advisory Committee	3.3yrs	Nessun dato	Nessun dato
Caroline Robert	Member of Scientific Advisory Committee	3.3yrs	Nessun dato	Nessun dato

3.3yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALVIO sono considerati esperti (durata media dell'incarico 3.3 anni).

Valerio Therapeutics Société anonyme Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Onxeo S.A. Appoints Khalil Barrage as New Board Member

Onxeo SA, Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Onxeo S.A. Announces Executive Changes

How Much Did Onxeo's (EPA:ALONX) CEO Pocket Last Year?

Onxeo SA Announces Board Changes

Recent updates

Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial

Onxeo SA to Report Fiscal Year 2022 Results on Mar 30, 2023

Onxeo SA Provides Update on the Development Program For Drug Candidate AsiDNATM

Onxeo SA Advances Its Second Lead Candidate Ox425 for the Treatment of Solid Tumors

Onxeo SA Announces the Enrollment of the First Patient in the Phase 1B/2 Clinical Study Conducted by the European Itcc Consortium and Sponsored by Institut Curie

Nasdaq Approves the Delisting of Onxeo's Shares from the First North Growth Market in Copenhagen

Onxeo Ordinary Shares to Be Deleted from OTC Equity

Onxeo SA Announces U.S. Food and Drug Administration Clears Initial IND Drug Candidate AsiDNA

Onxeo S.A. Appoints Khalil Barrage as New Board Member

Onxeo SA, Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Full year 2021 earnings released: €0.07 loss per share (vs €0.015 profit in FY 2020)

Onxeo S.A. Announces Executive Changes

Onxeo SA to Present New Preclinical Data Highlighting Asidna’s Ability to Fight Tumor Resistance and Protect from Anticancer Treatment Toxicity At Aacr Annual Meeting 2022

Onxeo SA to Present New Preclinical Data Highlighting Asidna’s Ability to Fight Tumor Resistance and Protect from Anticancer Treatment Toxicity At Aacr Annual Meeting 2022

Onxeo’s New Preclinical Data Confirm the Relevance of Combining AsiDNA™ With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors

Is Onxeo (EPA:ALONX) Weighed On By Its Debt Load?

First half 2021 earnings released: €0.057 loss per share (vs €0.075 profit in 1H 2020)

Onxeo S.A. Receives Notice of Allowance for New Patent Broadening the Protection of AsiDNA™ in Combination with a PARP Inhibitor in the United States

Onxeo's (EPA:ALONX) Earnings Are Built On Soft Foundations

Full year 2020 earnings released: EPS €0.01 (vs €0.55 loss in FY 2019)

Onxeo (EPA:ALONX) Share Prices Have Dropped 76% In The Last Five Years

Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a Phase 1b/2 Clinical Trial of AsiDN

Onxeo SA to Report First Half, 2021 Results on Jul 28, 2021

How Much Did Onxeo's (EPA:ALONX) CEO Pocket Last Year?

Onxeo SA's (EPA:ONXEO) Profit Outlook

Analysts update estimates

New 90-day high: €0.71

Onxeo S.A. Announces Completion of Patient Enrollment in DRIIV-1b Study

New 90-day low: €0.60

First half earnings released

New 90-day low: €0.65

First half earnings released

Onxeo SA Announces Board Changes

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media